This inventor holds 38 USPTO granted patents and 21 published patent applications, plus 4 CIPO patents and 32 EPO patents, primarily in Cancer Therapy. Top assignees: Hoffmann-La Roche Inc., C4 Therapeutics, Inc.. Active years: 2013-2026.
Location History:
- Grenchen, CH (2013)
- Basel, CH (2021)
- Birsfelden, CH (2013 - 2022)
- Biel-Benken, CH (2017 - 2024)
Company Filing History:
Years Active: 2013-2026
Areas of Expertise:
Sure, here is the article about inventor Antonio Ricci:
Title: Inventor Spotlight: Antonio Ricci
Introduction:
Antonio Ricci is a prolific inventor based in Birsfelden, Switzerland. With an impressive portfolio of 28 patents, he is a leading figure in the field of pharmaceutical innovations. Ricci's dedication to breakthrough research has led to the development of cutting-edge compounds that have the potential to revolutionize cancer treatments.
Latest Patents:
1. 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds: Ricci's invention provides compounds that serve as selective allosteric inhibitors of T790M and C797S containing EGFR mutants. These compounds are crucial in the manufacture of pharmaceutical compositions aimed at combating various diseases and have a significant impact on therapeutic treatments.
2. Isoindolinone and indazole compounds for the degradation of EGFR: In this patent, Ricci introduces compounds designed to degrade the epidermal growth factor receptor (EGFR), including mutant forms. This innovative approach involves the ubiquitination of the EGFR protein, leading to its proteasomal degradation. Such compounds play a vital role in the treatment of different types of cancers by targeting specific cellular pathways.
Career Highlights:
Throughout his career, Antonio Ricci has made significant contributions to the field of biopharmaceuticals. He has worked with reputable companies such as Hoffmann-La Roche Inc. and C4 Therapeutics, Inc., where his expertise and inventiveness have been instrumental in driving forward groundbreaking research and development initiatives.
Collaborations:
Ricci has collaborated with esteemed professionals in the industry, including Georg Jaeschke and Daniel Rueher. Together, they have shared insights, expertise, and innovative ideas, leading to the successful development and implementation of novel compounds and treatment strategies.
Conclusion:
Antonio Ricci's relentless pursuit of innovation and his unwavering commitment to advancing medical science have solidified his reputation as a trailblazer in the pharmaceutical industry. His contributions continue to inspire and pave the way for future breakthroughs in the treatment of complex diseases, offering hope for patients worldwide.